Australia's Racura Oncology gains on Purdue University cancer study collab
26/03/2026 24:30
** Racura Oncology RAC.AX rises as much as 4% to A$2.85, highest since March 25 ** Biopharma co commences research collaboration with Purdue University, Indiana, U.S. ** Collaboration to study molecular mechanisms within MYC gene promoter (MYCG4) to suppress MYC transcription in cancer ** RAC up 2.9% YTD (Reporting by Keshav Singh Chundawat in Bengaluru) ((Keshav.singhchundawat@thomsonreuters.com))
Recent news on Racura Oncology
See all newsAustralia's Racura Oncology jumps most in a month after raising $24 million
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220